B+
Bull case
25%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
VOR
Vor BiopharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The investment case rests on telitacicept as the company's focused asset, two global Phase 3 programs, prior China regulatory validation, and substantial liquidity. The prior company release projected funding into early 2029, but that runway has not been freshly reaffirmed in the post-print evidence.
Posture
Constructive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-09-10.
What can break
No reliable post-earnings consensus surprise, analyst revision, transcript, or event-attributed price reaction was available in the reviewed evidence.
Momentum
86
Value
41
Sentiment
79
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $25.00 · Bull $40.00 · Bear $12.00Analysis 2026-08-13; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-13 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $39.00
Why
Momentum86 · Δ7d -8.3
Value41 · Δ7d -0.0
Sentiment79 · Δ7d +11.1
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 2 setup hits (3d) with net bullish as of 2026-09-10.
- • Sentiment remains the lead driver in the composite, 7D delta +11.1.
Contradictions & invalidation
- • No reliable post-earnings consensus surprise, analyst revision, transcript, or event-attributed price reaction was available in the reviewed evidence.
- • Phase 3 efficacy, safety, enrollment, or regulatory setbacks could materially impair value.
- • The thesis remains binary and execution-dependent: Phase 3 enrollment and outcomes must support approval, the company has no commercial operating history, losses continue, and warrant liabilities create substantial balance-sheet and valuation noise.
Catalyst clock
2026-08-11
Q2 2026 filing confirms liquidity but highlights warrant and loss volatility
Lead driver: Sentiment · See AI snapshot
Momentum
86
9% active weight
Current posture
7d trendSoftening
Δ7d
-8.3
Δ21d
-11.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
79
62% active weight
Current posture
7d trendImproving
Δ7d
+11.1
Δ21d
+0.5
Why this grade
Composite grade A. Momentum 86.2 / Value 41.2 / Sentiment 79.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-13. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.36B
Beta
2.03
Shares Out
59.16M
P/E (TTM) · Derived
-0.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.30
Rev YoY
-
EPS YoY
-99.5%
Gross Margin
-
Op Margin
-
Net Debt
-$452.21M
Current Ratio
19.15
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data